8-K - REGENXBIO Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On March 18, 2026, REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve a dispute over sublicense fees under their 2009 License Agreement. The Company will pay $10.0 million to GSK within three business days, securing mutual releases of past claims and certain future claims while continuing existing payment practices.

Key Takeaways

1Entered Settlement and Release Agreement with GlaxoSmithKline LLC on March 18, 2026

2Payment of $10.0 million to GSK within three business days for alleged underpayment of sublicense fees

3Resolves dispute related to License Agreement dated March 6, 2009, as amended on April 15, 2009

4Mutual releases of all past claims and certain specified future claims under the GSK-REGENXBIO Sublicense

5Company to continue paying GSK using existing allocation methodology

Current Report Details

Event Type

Material Agreement

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement

Material Agreement

$10.0M

Transaction Details

Material Agreement

Agreement: Settlement and Release Agreement
Parties: REGENXBIO Inc., GlaxoSmithKline LLC (GSK)

•Company will make a payment of $10.0 million to GSK within three business days of the Settlement Agreement effective date for alleged underpayment of sublicense fees on amounts received from sublicensees, including royalties
•Mutual releases of (a) all past claims arising out of or related to the GSK-REGENXBIO Sublicense and (b) certain specified types of future claims arising out of or related to the GSK-REGENXBIO Sublicense
•Company will continue to pay GSK amounts received from sublicensees pursuant to existing sublicense agreements, utilizing the Company’s existing allocation methodology

Exhibits (1)

8-K